Kelun-Biotech’s Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378
CHENGDU, China, July 23, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”, HKEX: 6990) today announced that its partner, Windward Bio AG (“Windward Bio”) has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB378/WIN378 for people living with asthma. SKB378/WIN378 is a novel, recombinant fully human monoclonal antibody (mAb) that potently […]







